By targeting these two pathways, ZD6474 has the potential to offer the combined benefits of directly inhibiting tumour cell proliferation and survival like other EGFR inhibitors, as well as inhibiting tumour angiogenesis by inhibiting VEGF activity. The gene discussed is EGFR; the disease is neoplasm.